Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

RNA Splicing01:32

RNA Splicing

60.4K
Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
60.4K
Alternative RNA Splicing02:18

Alternative RNA Splicing

24.7K
Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
24.7K
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

14.6K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
14.6K
Exon Recombination02:32

Exon Recombination

4.1K
The evolution of new genes is critical for speciation. Exon recombination, also known as exon shuffling or domain shuffling, is an important means of new gene formation. It is observed across vertebrates, invertebrates, and in some plants such as potatoes and sunflowers. During exon recombination, exons from the same or different genes recombine and produce new exon-intron combinations, which might evolve into new genes. 
Exon shuffling follows “splice frame rules.” Each exon...
4.1K
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

5.4K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
5.4K
Mismatch Repair01:20

Mismatch Repair

6.3K
Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
6.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Deficiency of Krüppel-like factor 15 activates β-catenin and is involved in the development of osteoarthritis : Author.

Arthritis research & therapy·2026
Same author

Behavioral and Self-Report Measures of Spontaneous Mind Wandering Predict Different Aspects of ADHD in Adults.

Journal of attention disorders·2026
Same author

[Development and Accuracy Evaluation of the Beam Width Using a Tungsten Ring in a Wide-beam CT System].

Nihon Hoshasen Gijutsu Gakkai zasshi·2026
Same author

Ruptured Uterine Leiomyosarcoma With Heterologous Components Including Osteosarcoma and Chondrosarcoma.

Journal of medical cases·2026
Same author

Basic characteristics of do-it-yourself dosimeter in general radiography system.

Radiological physics and technology·2026
Same author

Two-decade trends in prenatal genetic testing in Japan.

Journal of human genetics·2026

Related Experiment Video

Updated: Jan 16, 2026

Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells
10:06

Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells

Published on: April 26, 2017

9.4K

Problems in Cancer Genome Medicine: Base Mutations Cause Intron Start Signals, Resulting in Unexpected Splicing.

Takuma Hayashi1, Ikuo Konishi1,2

  • 1Cancer Medicine, National Hospital Organization Kyoto Medical Center, Kyoto-city, Kyoto 612-8555, Japan.

World Journal of Oncology
|October 1, 2025
PubMed
Summary

Cancer gene panel testing can misidentify variants of unknown significance (VUS). Further investigation is crucial for accurate diagnosis and treatment of hereditary tumors, especially when mutations affect splicing.

Keywords:
Cancer gene panelPathogenic variantSplicingVUS

More Related Videos

A Reporter Based Cellular Assay for Monitoring Splicing Efficiency
08:53

A Reporter Based Cellular Assay for Monitoring Splicing Efficiency

Published on: September 15, 2021

3.2K
Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models
09:58

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

14.3K

Related Experiment Videos

Last Updated: Jan 16, 2026

Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells
10:06

Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells

Published on: April 26, 2017

9.4K
A Reporter Based Cellular Assay for Monitoring Splicing Efficiency
08:53

A Reporter Based Cellular Assay for Monitoring Splicing Efficiency

Published on: September 15, 2021

3.2K
Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models
09:58

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

14.3K

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Cancer gene panel testing analyzes genetic mutations in tumors to guide targeted therapy.
  • Variants of unknown significance (VUS) present diagnostic challenges, with potential racial disparities in their clinical relevance.
  • Understanding VUS is critical for accurate cancer diagnosis and treatment selection.

Purpose of the Study:

  • To re-evaluate cancer gene panel testing (CGP) results, particularly variants of unknown significance (VUS), in patients with suspected hereditary tumors.
  • To investigate the impact of VUS on gene splicing and mRNA production.
  • To highlight the need for detailed examination of gene mutations beyond initial CGP findings.

Main Methods:

  • Re-examination of CGP results for VUS in patients with hereditary tumor risk using IGV and RT-PCR.
  • Analysis of specific VUS in KRAS, SDHB, and BRCA2 genes.
  • Correlation of VUS with potential splicing defects.

Main Results:

  • Identified KRAS Q61K as a VUS that affects splicing in gastrointestinal cancers.
  • SDHB G642T, initially a VUS, was found to cause splicing site shifts, leading to non-functional SDHB protein.
  • BRCA2 631 3A>T, classified as a VUS, was observed to potentially create a splicing site, disrupting normal BRCA2 mRNA production.

Conclusions:

  • Cancer gene panel testing diagnoses may require further validation, especially for VUS.
  • Detailed analysis, including splicing impact, is essential for accurate interpretation of genetic mutations.
  • Experience with over 5,500 cases informs ongoing research into novel treatments for intractable tumors.